SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that its Board of Directors has appointed Clint Carnell, 45, President, Chief Executive Officer, and member of the Board of Directors, effective immediately. Carnell succeeds Harold (Butch) R. Wolcott, who announced in April 2014 his intent to step down as CEO upon the hiring of a successor.
Mr. Carnell brings a 23-year track record of success leading and creating new value at medical device companies at all stages of growth from venture capital-funded, Silicon Valley start-ups to Fortune 500 organizations. Most recently, he served as an advisor to Covidien plc, a publicly traded global health care leader, in the role of 'Executive in Residence.' Previously, Mr. Carnell served as Chairman, Chief Executive Officer and President of MyoScience, Inc., a commercial-stage medical device company; Chief Operating Officer of Solta Medical, Inc., a leading medical aesthetics company; and Vice President of Sales for the Surgical Division of Bausch & Lomb.
“I believe BSD’s MicroThermX® system is the leading technology in the disruptive, high growth microwave ablation market,” said Mr. Carnell. “I look forward to leading BSD and helping build awareness among patients, physicians and the healthcare system of the advantages of this treatment option for diseased, soft tissue cancerous tumors. In the coming months, I look forward to sharing our plan for creating shareholder value by executing a successful and strategic commercial rollout for MicroThermX®.”
“Clint’s extensive and proven success in leading medical device businesses that are focused on commercialization, make him the ideal leader for BSD’s next phase of growth and development,” said BSD Chairman Timothy C. McQuay. “He has tremendous enthusiasm for our technology and a vision for driving growth and success. He also has substantial public company experience, including working with the investment community. We conducted a comprehensive search to find the right CEO for BSD and we are delighted to welcome Clint to our company.
“On behalf of the Board and staff at BSD, I would like to express our gratitude to Butch for his outstanding dedication, leadership and hard work over the past five years as CEO. We look forward to his continued contribution to the Company as a member of the Board.”
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts, including statements relating to our 2015 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.